作者
Paul S. Myles,Jan M. Dieleman,K. E. Munting,Andrew Forbes,Catherine Martin,Julian A. Smith,David C. McGiffin,Lieke P. J. Verheijen,Sophie Wallace,Paul S. Myles,Sophie Wallace,M. Ueoka,Mary Ann Dutton,Stacey Robertshaw,M. Clarris,Aimee Neylan,Julian A. Smith,Amanda Hulley,S. Warwarek,Thomas Painter,Kathy Heyman,R. Falland,J. Pieterse,Roanne Fiddes,Andrew Marriott,Jan M. Dieleman,Jennifer R. Cope,Elenore Clark-MacKay,K. E. Munting,Lieke P. J. Verheijen,D. van Dijk,Nicobert E. Wietsma,N. P. Monteiro de Olivieira,Liam Oey
摘要
High-dose corticosteroids have been used to attenuate the inflammatory response to cardiac surgery and cardiopulmonary bypass, but patient outcome benefits remain unclear. The primary aim was to determine whether using dexamethasone was superior to not using dexamethasone to increase the number of home days in the first 30 days after cardiac surgery. The secondary aim was to evaluate efficiency, value, and impact of the novel trial design.